Wissenschaftliche Arbeit

  1. 07/2022 Aust, E., Linse, K., Graupner, S.-T., Joos, M., Liebscher, D., Grosskreutz, J., .... Hermann, A. (2022). Quality of life and mental health in the locked-in-state—Differences between patients with amyotrophic lateral sclerosis and their next of kin. Journal of Neurology. https://doi.org/10.1007/s00415-022-11238-0
  2. 02/2022 Schmitz-Peiffer, H*, Aust, E,* Linse, K, Rueger, W, Joos, M, Löhle, M, Storch, A, & Hermann, A. Motor-Independent Cognitive Testing in Motor Degenerative Diseases. Journal of Clinical Medicine, 11(3), 814. https://doi.org/10.3390/jcm11030814. *geteilte Erstautorenschaft
  3. 01/2022 Linse, K, Aust, E, Günther, R, & Hermann, A. Caregivers’ View of Socio-Medical Care in the Terminal Phase of Amyotrophic Lateral Sclerosis—How Can We Improve Holistic Care in ALS? Journal of Clinical Medicine, 11(1), 254. https://doi.org/10.3390/jcm11010254. 
  4. 06/2021 Freigang M, Steinacker P, Wurster CD, Schreiber-Katz O, Osmanovic A, Petri S, Koch JC, Rostásy K, Falkenburger B, Ludolph AC, Otto M, Hermann A, Günther R. Increased Chitotriosidase1 Concentration Following Nusinersen Treatment in Spinal Muscular Atrophy. Orphanet J Rare Dis (2021) 16:330 https://doi.org/10.1186/s13023-021-01961-8
  5. 06/2021 Schischlevskij P, Cordts I, Günther R, Stolte B, …, Hagenacker T, Deschauer M, Lingor P, Petri S, Schreiber-Katz O. Informal Caregiving in Amyotrophic Lateral Sclerosis (ALS): A High Caregiver Burden and Drastic Consequences on Caregivers’ Lives. Brain Sci. 2021, 11(6), 748; https://doi.org/10.3390/brainsci11060748
  6. 05/2021 Becker L, Weiss C, Günther R, Hermann A, Theophile M, Hübner A, Smitka M, Hagen M, Kaindl A. Evaluation of metabolic effects of nusinersen in patients with spinal muscular atrophy. Journal of Pediatric Neurology.
  7. 05/2021 Meyer T, Maier A, Uzelac Z, Hagenacker T, Günther R, Schreiber-Katz O, Markus Weiler, …Spittel S. Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen. European Journal of Neurology. doi.org/10.1111/ene.14902
  8. 03/2021 Freigang M, Wurster CD, Hagenacker T, Stolte B, Weiler M, Kamm C, Schreiber-Katz O, Osmanovic A, Petri S, Kowski A, Meyer T, Koch JC, Cordts I, Deschauer M, Lingor P, Aust E, Petzold D, Ludolph AC, Falkenburger B, Hermann A*, Günther R*. Serum creatine kinase and creatinine are promising biomarkers in adult spinal muscular atrophy. Ann Clin Transl Neurol. doi: 10.1002/acn3.51340 *geteilte Letztautoren
  9. 03/2021 Peseschkian T, Cordts I, Günther R, Stolte B, Zeller D, Schröter C, Weyen U, Regensburger M, Wolf J, Schneider I, Hermann A, Metelmann M, Kohl Z, Linker R, … Ludolph AC, Boentert M, Hagenacker T, Deschauer M, Lingor P, Petri S and Schreiber-Katz O. A Nation-Wide, Multi-Center Study on the Quality of Life of ALS Patients in Germany. Brain Sci. 2021, 11, 372. https://doi.org/10.3390/brainsci11030372
  10. 02/2021 Vidovic M, Aust E, Hermann A, Günther R. The palmomental reflex in amyotrophic lateral sclerosis – A clinical sign of executive or motor dysfunction? Amyotroph Lateral Scler Frontotemporal Degener. 2021 Mar 3;1-4. doi: 10.1080/21678421.2021.1883667
  11. 02/2021 Osmanovic A , RanxhaG; Kumpe M; Wurster CD, Stolte B, Cordts I, Günther R, Freigang M, Müschen L; Binz C, Hermann A, Deschauer M, Lingor P, Ludolph AC, Hagenacker T, Schreiber-Katz O, Petri S. Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy. Therapeutic advances in neurological disorders. 2021 Mar 5; doi: 10.1177/1756286421998902
  12. 02/2021 Pal A, Kretner B, Abo-Rady M, Glaβ H, Dash BP, Naumann M, Japtok J, Kreiter N, Dhingra A, Heutink P, Böckers T, Günther R, Sterneckert J, Hermann A. Concomitant gain and loss of function pathomechanisms in C9ORF72 amyotrophic lateral sclerosis. Life Science Alliance. 2021 Feb 22. doi: 10.26508/lsa.202000764
  13. 02/2021 Lingor P, Koch JC, Statland JM, …, Günther R, … Benatar M. Challenges and opportunities for Multi-National Investigator-Initiated clinical trials for ALS: European and United States collaborations. Amyotroph Lateral Scler Frontotemporal Degener. 2021 Feb 3;1-7. doi: 10.1080/21678421.2021.1879866.
  14. 01/2021 Szewczyk B, Günther R, Sterneckert J, Petri S, Wegner F, Hermann A. FUS Is Not Mislocalized in Spinal Motor Neurons Derived from Human Induced Pluripotent Stem Cells of Main Non-FUS ALS Subtypes. J Neuropathol Exp Neurol. 2021 Jan 15;nlaa154. doi: 10.1093/jnen/nlaa154
  15. 12/2020 Loewenbrück KF, Werner R, Günther R, Dittrich M, Klinkenberger R, Machetanz J, Reichmann H, Storch A, Hermann A. One nerve suffices: A clinically guided nerve ultrasound protocol for the differentiation of multifocal motor neuropathy (MMN) and amyotrophic lateral sclerosis (ALS). J Neurol. 2020 Dec 23. doi: 10.1007/s00415-020-10323-6
  16. 11/2020 Beyer L*, Günther R*, Koch JC, Klebe S, Hagenacker T, Lingor P, Biesalski A, Hermann A, Nabers A, Gold R, Tönges L, Gerwert K. TDP-43 as Structure-Based Biomarker in Amyotrophic Lateral Sclerosis. Ann Clin Transl Neurol. 2020 Dec 2. doi: 10.1002/acn3.51256* geteilte Erstautoren
  17. 09/2020 Wurster CD, Günther R. Innovative Therapiestrategien bei der spinalen Muskelatrophie (SMA). Kompendium ZNS Thieme
  18. 05/2020 Bräuer S, Günther R, Sterneckert J, Glaß H, Hermann A. Human Spinal Motor Neurons Are Particularly Vulnerable to Cerebrospinal Fluid of Amyotrophic Lateral Sclerosis Patients. Int J Mol Sci. 21(10):3564
  19. 04/2020 Meyer T, Kettemann D, Maier A, Grehl T, Weyen U, Grosskreutz J, Steinbach J, Norden J, George A, Hermann A, Günther R, Petri S, Schreiber- Katz O, Dorst J, Ludolph AC, Walter B, Münch C, Spittel S. Symptomatic pharmacotherapy in ALS: data analysis from a platform-based medication management programme. JNNP. 91(7):783-785
  20. 03/2020 Hagenacker T*, Wurster CD*, Günther R*, Schreiber-Katz O, Osmanovic A, Petri S, Weiler M, Ziegler A, Kuttler J, Koch JC, Schneider I, Wunderlich G, Schloss N, Lehmann HC, Cordts I, Deschauer M, Lingor P, Kamm C, Stolte B, Pietruck L, Totzeck A, Kizina K, Mönninghoff C, von Velsen O, Ose C, Reichmann H, Forsting M, Pechmann A, Kirschner J, Ludolph AC, Hermann A, Kleinschnitz C. Nusinersen in adults with 5q spinal muscular atrophy: non-interventional, multicentre, observational cohort study. Lancet Neurol. 19(4):317-325 * geteilte Erstautoren
  21. 03/2020 Mengmeng J*, Günther R*, Akgün K, Hermann A, Ziemsse T. Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis. Scientific Reports. 10(1):5941 * geteilte Erstautoren
  22. 02/2020 Wurster CD, Günther R. Neue Therapien der spinalen Muskelatrophie - New treatments for spinal muscular atrophy. Der Nervenarzt. 91(4):294-302
  23. 12/2019 Hagenacker T, Hermann A, Kamm C, Walter MC, Weiler M, Günther R, Wurster CD, Kleinschnitz C. Spinale Muskelatrophie - Expertenempfehlungen zur Behandlung von erwachsenen Patienten mit Nusinersen / Spinal Muscular Atrophy – expert recommendations for the use of nusinersen in adult patients. Fortschritte der Neurologie – Psychiatrie. 87(12):703-710
  24. 11/2019 Wurster CD, Koch JC, Cordts I, Dreyhaupt J, Otto M, Uzelac Z, Witzel S, Winter B, Kocak B, Schocke M, Weydt P, Wollinsky K, Ludolph AC, Deschauer M, Lingor P, Tumani H, Hermann A, Günther R. Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen. Front Neurol. 10:1179
  25. 11/2019 Günther R, Wurster CD, Cordts I, Koch JC, Kamm C, Petzold D, Aust E, Deschauer M, Lingor P, Ludolph AC, Hermann A. Patient-Reported Prevalence of Non-motor Symptoms Is Low in Adult Patients Suffering From 5q Spinal Muscular Atrophy. Front Neurol. 10:1098
  26. 11/2019 Naumann M, Peikert K, Günther R, van der Kooi AJ, Aronica E, Hübers A, Danel V, Corcia P, Pan-Montojo F, Cirak S, Haliloglu G, Ludolph AC, Goswami A, Andersen PM, Prudlo J, Wegner F, Van Damme P, Weishaupt JH, Hermann A. Phenotypes and malignancy risk of different FUS mutations in genetic amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 6(12):2384-2394
  27. 09/2019 Wurster CD*, Steinacker P*, Günther R, Koch JC, Lingor P, Uzelac Z, Witzel S, Wollinsky K, Winter B, Osmanovic A, Schreiber-Katz O, Al Shweiki R, Ludolph AC, Petri S, Hermann A, Otto M. Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen. Journal of Neurology. 267(1):36-44
  28. 04/2019 Wurster C, Günther R, Steinacker P, Dreyhaupt J, Wollinsky K, Uzelac Z, Witzel S, Kocak T, Winter B, Koch JC, Lingor P, Petri S, Ludolph AC, Hermann A, Otto M. Neurochemical markers in CSF of adolescent and adult SMA patients under treatment with nusinersen. Ther Adv Neurol Disord. 12: 1–8
  29. 04/2019 Lingor P, Weber M, Camu W, Friede T, Hilgers R, Leha A, Neuwirth C, Günther R, Benatar M, Kuzma-Kozakiewicz M, Bidner H, Blankenstein C, Frontini R, Ludolph A, Koch JC and the ROCK-ALS Investigators ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis. Front Neurol. 10:293
  30. 04/2019 Peikert K, Naumann M, Günther R, Wegner F, Hermann A. Off-Label Treatment of 4 Amyotrophic Lateral Sclerosis Patients With 4-Aminopyridine. J Clin Pharmacol. 59(10):1400-1404
  31. 01/2019 Walter MC, Dräger B, Günther R, Hermann A, Hagenacker T, Kleinschnitz C, Löscher W, Meyer T, Schrank B, Schwersenz I, Wurster CD, Ludolph AC, Kirschner J (2019): Therapieevaluation bei Patienten mit 5q-assoziierter Spinaler MuskelatrophieErfahrungen aus der klinischen Praxis. Der Nervenarzt. 90(4):343-351
  32. 01/2019 Winter B, Günther R, Ludolph AC, Hermann A, Otto M, Wurster CD. Neurofilaments and tau in CSF in an infant with SMA type 1 treated with nusinersen. JNNP. 90(9):1068-1069
  33. 02/2019 Günther R, Neuwirth C, Koch JC, Lingor P, Braun N, Untucht R, Petzold D, Weber M, and Hermann Motor Unit Number Index (MUNIX) of hand muscles is a disease biomarker for adult spinal muscular atrophy. Clin Neurophysiol. 130(2):315-319
  34. 02/2018 Günther R, Schrempf W, Hähner A, Hummel T, Wolz M, Storch A, Hermann A. Impairment in respiratory function contributes to olfactory impairment in Amyotrophic Lateral Sclerosis. Front. Neurol. 9:79
  35. 07/2018 Linse, K, Aust, E*, Joos, M, & Hermann, A. Communication Matters—Pitfalls and Promise of Hightech Communication Devices in Palliative Care of Severely Physically Disabled Patients With Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 9. https://doi.org/10.3389/fneur.2018.00603. *geteilte Erstautorenschaft
  36. 01/2018 Naumann M, Pal A, Goswami A, Lojewski X, Japtok J, Vehlow A, Naujock M, Günther R, …, Hermann A. Impaired DNA damage response signaling by FUS-NLS mutations leads to neurodegeneration and FUS aggregate formation. Nat Commun. 23;9(1):335
  37. 01/2017 Günther R, Balck A, Koch JC, Nientiedt T, Sereda M, Bähr M, Lingor P, Tönges L. Rho Kinase Inhibition with Fasudil in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis-Symptomatic Treatment Potential after Disease Onset. Front Pharmacol. 8:17
  38. 07/2016 Günther R, Richter N, Sauerbier A, Chaudhuri KR, Martinez-Martin P, Storch A, Hermann A. Non-Motor Symptoms in Patients Suffering from Motor Neuron Diseases. Front Neurol. 7:117
  39. 10/2014 Günther R, Saal KA, Suhr M, Scheer D, Koch JC, Bähr M, Lingor P, Tönges L. The rho kinase inhibitor Y-27632 improves motor performance in male SOD1(G93A) mice. Front Neurosci. 8:304
  40. 02/2014 Tönges L, Günther R, Suhr M, Jansen J, Balck A, Saal K, Barski E, Nientied T, Götz AA, Koch J et al.. Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis. Glia. 62(2):217-32
  41. 03/2012 Günther R, Suhr M, Koch JC, Bähr M, Lingor P, Tönges L. Clinical testing and spinal cord removal in a mouse model for amyotrophic lateral sclerosis (ALS). J Vis Exp. (61):3936